Replimune Group, Inc(NASDAQ:REPL) 
Replimune Group, Inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a...
Website: http://www.replimune.com
Founded: 2015
Full Time Employees: 122
Sector: Healthcare
Industry: Biotechnology
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-03
P
O 8.35
H 8.38
L 7.86
C 7.89
V 919,171
10EMA 7.89
20EMA 7.89
60EMA 7.89
120EMA 7.89
250EMA 7.89